Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
FFAR3 Biologics Sequence Review Report 2026: Free fatty acid receptor 3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FFAR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FFAR1 Biologics Sequence Review Report 2026: Free fatty acid receptor 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FFAR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GABRD Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit delta Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GABRD protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IRS4 Biologics Sequence Review Report 2026: Insulin receptor substrate 4 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IRS4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GOSR2 Biologics Sequence Review Report 2026: Golgi SNAP receptor complex member 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GOSR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PEX7 Biologics Sequence Review Report 2026: Peroxisomal targeting signal 2 receptor Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PEX7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GABRP Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit pi Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GABRP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PITPNM1 Biologics Sequence Review Report 2026: Membrane-associated phosphatidylinositol transfer protein 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PITPNM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD1E Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD1e, membrane-associated Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD1E protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CD99 Biologics Sequence Review Report 2026: CD99 antigen Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD99 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD8B Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD8 beta chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD8B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
NR5A2 Biologics Sequence Review Report 2026: Nuclear receptor subfamily 5 group A member 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of NR5A2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
186
187
188
189
190
>>
1503
>